A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N0775

Cancer

Volumn 119, Issue 3, 2013, Pages 586-592

  Kottschade, Lisa A ^a   Suman, Vera J ^a   Perez, Domingo G ^b   McWilliams, Robert R ^a   Kaur, Judith S ^a   Amatruda III, Thomas T ^b   Geoffroy, Francois J ^c   Gross, Howard M ^d   Cohen, Peter A ^e   Jaslowski, Anthony J ^f   Kosel, Matthew L ^a   Markovic, Svetomir N ^a  

^a MAYO CLINIC   (United States)

^b Metro Minnesota Community Clinical Oncology Program (CCOP)   (United States)

^c Illinois Oncology Research Association CCOP   (United States)

^d Dayton Clinical Oncology Program CCOP Hematology and Oncology of Dayton Inc   (United States)

^e MAYO CLINIC   (United States)

^f St Vincent Regional Cancer Center CCOP   (United States)

Author keywords

chemotherapy; combination therapy; metastatic melanoma; unresectable metastatic melanoma; vascular endothelial growth factor inhibition

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; TEMOZOLOMIDE; VASCULOTROPIN A; VASCULOTROPIN D;

ABDOMINAL BLEEDING; ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ENDOTHELIUM CELL; FATIGUE; FEMALE; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PANCREATITIS; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DACARBAZINE; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84872956413     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27760     Document Type: Article

References (19)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta, GA: American Cancer Society. http://www.cancer.org/Research/CancerFactsFigures/ CancerFactsFigures/cancer-facts-and-figures-2010. Accessed January 25, 2011.
2. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17: 2105-2116.
3. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158-166.
4. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723.
5. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364: 2507-2516.
6. Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363: 809-819.
7. Salven P, Heikkila P, Joensuu H,. Enhanced expression of vascular endothelial growth factor in metastatic melanoma. Br J Cancer. 1997; 76: 930-934.
8. Ugurel S, Rappl G, Tilgen W, Reinhold U,. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 2001; 19: 577-583.
9. Lev DC, Onn A, Melinkova VO, et al. Exposure of melanoma cells to dacarbazine results in enhanced tumor growth and metastasis in vivo. J Clin Oncol. 2004; 22: 2092-2100.
10. Lev DC, Ruiz M, Mills L, McGary EC, Price JE, Bar-Eli M,. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther. 2003; 2: 753-763.
11. Ferrara N, Hillan KJ, Gerber HP, Novotny W,. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004; 3: 391-400.
12. Perez DG, Suman VJ, Fitch TR, et al. Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A. Cancer. 2009; 115: 119-127.
13. O'Day SK, Sosman J, Peterson A, et al. BEAM: a randomized phase II study evaluating the activity of BEvacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated Advanced Melanoma. Eur J Cancer Suppl. 2009; 7: 13.
14. Kim KB, Sosman JA, Fruehauf JB, et al. BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol. 2012; 30: 34-41.
15. Papiewska-Pajak I, Boncela J, Przygodzka P, Cierniewski CS,. Autocrine effects of VEGF-D on endothelial cells after transduction with AD-VEGF-D(DeltaNDeltaC). Exp Cell Res. 2010; 316: 907-914.
16. Kottschade LA, Suman VJ, Amatruda T,3rd et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a north central cancer treatment group study, N057E1. Cancer. 2011; 117: 1704-1710.
17. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol. 2008; 26: 527-534.
18. von Moos R, Seifert B, Simcock M, et al. Swiss Group for Clinical Cancer Research (SAKK). First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicenter phase II trial (SAKK 50/07). Ann Oncol. 2012; 23: 531-536.
19. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol. 2009; 27: 2823-2830.